Rituximab therapy in nephrotic syndrome: implications for patients' management | Nature Reviews Nephrology
Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial - The Lancet Rheumatology
Rituximab zum Schutz der Betazellen | PZ – Pharmazeutische Zeitung
Autoimmunerkrankungen des ZNS: B-Zelldepletion mit Rituximab beugt Rückfällen der Neuromyelitis optica vor
Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes | Genes & Immunity
PDF) Rituximab Selectively Suppresses Specific Islet Antibodies
Current and future therapies for type 1 diabetes | SpringerLink
New therapeutic approaches for type 1 diabetes: Disease-modifying therapies
Rituximab Selectively Suppresses Specific Islet Antibodies Trialnet-Yu et al Diabetes ppt download
POS1238 GLUCOCORTICOIDS, RITUXIMAB AND THE PRESENCE OF INTERSTITIAL LUNG DISEASE ARE ASSOCIATED WITH POOR OUTCOMES OF THE SARS-COV-2 INFECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE NATIONAL REGISTRY SAR-COVID. | Annals
B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results
Warum Rituximab bei manchen Patienten mit CLL und anderen Lymphomen nicht so gut wirkt
Rituximab Treatment Modulates the Release of Hydrogen Peroxide and the Production of Proinflammatory Cytokines by Monocyte at the Onset of Type 1 Diabetes | Bentham Science
Refractory Pituitary Granulomatosis with Polyangiitis (Wegener's) Treated with Rituximab - Endocrine Practice
Diabetes und rheumatische Erkrankungen in der Covid-19-Pandemie | Gelbe Liste
![PDF] Immune Interventions to Preserve Beta Cell Function in Type 1 Diabetes | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d152545eac07d3a073b27760de34a2ebe1da5823/14-Figure1-1.png "PDF] Immune Interventions to Preserve Beta Cell Function in Type 1 Diabetes | Semantic Scholar")
PDF] Immune Interventions to Preserve Beta Cell Function in Type 1 Diabetes | Semantic Scholar
Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial - The Lancet Oncology
JCI - B cell depletion: a novel therapy for autoimmune diabetes?
B-cell depletion with CD20 (Rituximab). Anti-CD20 mAb can direct the... | Download Scientific Diagram
Immunsuppressivum Rituximab erhöht Sterberisiko bei COVID-19 deutlich
JCI Insight - Cell type–specific immune phenotypes predict loss of insulin secretion in new-onset type 1 diabetes
Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function | NEJM
Hypertonie und Diabetes als Risikofaktoren? – Rosenfluh.ch
Rituximab - Wikipedia
Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group - ScienceDirect
Decreased interleukin-35 levels and CD4+EBI3+ T cells in patients with type 1 diabetes and the effects of the antibody against CD20 (rituximab)
